Lipfendra offers patients a once-daily pill alternative to injectable PCSK9 therapies

The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral medication that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), offering a new treatment option for adults with high cholesterol and certain inherited forms of the disease.

The approval represents an important milestone in cardiovascular medicine because existing PCSK9 inhibitors, among the most effective cholesterol-lowering therapies available, have previously required injection.

Lipfendra is taken as a once-daily oral tablet and is approved for use alongside diet, exercise, and maximally tolerated statin therapy.

Why This Matters

High levels of low-density lipoprotein cholesterol (LDL-C), commonly known as “bad cholesterol,” are a major contributor to heart disease and stroke.

While statins remain the first-line treatment for most patients, many individuals either require additional LDL lowering or are unable to achieve recommended cholesterol targets.

PCSK9 inhibitors have transformed cholesterol management by dramatically lowering LDL cholesterol, but their injectable administration has limited acceptance among some patients.

Lipfendra is the first medication to provide PCSK9 inhibition in an oral formulation.

Clinical Results

FDA based its approval on two randomized, placebo-controlled Phase 3 clinical trials involving more than 3,200 patients.

Among adults with established or high-risk cardiovascular disease receiving maximally tolerated statin therapy, LDL cholesterol decreased approximately 56% compared with placebo after 24 weeks.

Among patients with heterozygous familial hypercholesterolemia (HeFH), LDL cholesterol decreased approximately 59% compared with placebo.

These reductions are comparable to those achieved by currently available injectable PCSK9 therapies.

Safety Profile

Overall adverse events were similar between Lipfendra and placebo.

The most frequently reported adverse reactions among patients with familial hypercholesterolemia included diarrhea and dizziness.

Treatment discontinuation rates due to adverse events were similar between treatment groups.

Potential Impact

Cardiovascular disease remains the leading cause of death in the United States. An effective oral PCSK9 inhibitor may improve patient acceptance and long-term adherence by eliminating the need for routine injections.

For patients who require aggressive cholesterol lowering despite statin therapy, Lipfendra could expand access to one of the most effective lipid-lowering mechanisms currently available.

FDA granted Lipfendra Priority Review, recognizing the potential importance of the therapy.

The drug was developed by Merck Sharp & Dohme LLC.

MDP Perspective

Although this approval introduces a new medication, its broader significance lies in drug delivery innovation.

PCSK9 inhibition has been available for several years through injectable biologic therapies. Lipfendra demonstrates that advances in pharmaceutical science can sometimes improve patient care not by discovering a completely new therapeutic target, but by making an established therapy easier for patients to use.

Medication adherence remains one of the largest challenges in chronic disease management. For many patients, replacing injectable therapy with a once-daily tablet has the potential to improve long-term treatment persistence while maintaining substantial LDL cholesterol reduction.

From a regulatory perspective, this approval also illustrates FDA’s willingness to prioritize therapies that provide meaningful advances in patient convenience, accessibility, and treatment adherence in addition to clinical effectiveness.